Progress of Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Treatment of Neonatal Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia(BPD)is a chronic lung disease of preterm infants,par-ticularly being the most common complication among extremely preterm infants(those born with a gestational age of less than 32 weeks).Despite advances in perinatal treatment and care,mod-ern clinical management still lacks therapies specifically designed to promote lung repair and growth.Mesenchymal stem cells(MSCs)are a type of stem cells with multi-differentiation po-tential,and recent advances have revealed their potential to repair damaged organs through stem/progenitor cell-mediated regeneration.However,clinical risks associated with MSCs have hin-dered their broader applications.Research indicates that in BPD animal models,MSC-derived ex-tracellular vesicles(MSC-EVs)manage to promote pulmonary angiogenesis,facilitate alveolar development,reduce pulmonary arterial hypertension,and alleviate pulmonary inflammation by downregulating fibrotic factors,alleviating inflammatory responses,and promoting angiogenesis,anti-apoptosis,and resistance to oxidative stress.Therefore,they play critical roles in the repair of lung injuries associated with BPD.This article reviews the potential preclinical evidence and possible mechanisms of MSC-EV-associated therapy in the treatment of neonatal BPD,providing new therapeutic insights for its future clinical application in neonatal BPD.
万方数据
维普
